Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2021 3
2022 4
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

9 results

Results by year

Filters applied: . Clear all
Page 1
Serum-derived extracellular vesicles from breast cancer patients contribute to differential regulation of T-cell-mediated immune-escape mechanisms in breast cancer subtypes.
Graham R, Gazinska P, Zhang B, Khiabany A, Sinha S, Alaguthurai T, Flores-Borja F, Vicencio J, Beuron F, Roxanis I, Matkowski R, Liam-Or R, Tutt A, Ng T, Al-Jamal KT, Zhou Y, Irshad S. Graham R, et al. Among authors: alaguthurai t. Front Immunol. 2023 Jun 22;14:1204224. doi: 10.3389/fimmu.2023.1204224. eCollection 2023. Front Immunol. 2023. PMID: 37441083 Free PMC article.
Transcriptomic analysis of the TCGA data identified that samples assigned with lower EV scores had significantly higher abundance of CD4+ memory activated T cells, T follicular cells and CD8 T cells, plasma, and memory B cells; whilst samples with high EV sco …
Transcriptomic analysis of the TCGA data identified that samples assigned with lower EV scores had significantly higher abundance of CD4+ me …
Dynamic Changes in the NK-, Neutrophil-, and B-cell Immunophenotypes Relevant in High Metastatic Risk Post Neoadjuvant Chemotherapy-Resistant Early Breast Cancers.
Gazinska P, Milton C, Iacovacci J, Ward J, Buus R, Alaguthurai T, Graham R, Akarca A, Lips E, Naidoo K, Wesseling J, Marafioti T, Cheang M, Gillett C, Wu Y, Khan A, Melcher A, Salgado R, Dowsett M, Tutt A, Roxanis I, Haider S, Irshad S. Gazinska P, et al. Among authors: alaguthurai t. Clin Cancer Res. 2022 Oct 14;28(20):4494-4508. doi: 10.1158/1078-0432.CCR-22-0543. Clin Cancer Res. 2022. PMID: 36161312 Free PMC article.
BNT162b2 COVID-19 and ChAdOx1 nCoV-19 vaccination in patients with myelodysplastic syndromes.
Abdul-Jawad S, Beatson R, Lechmere T, Graham R, Alaguthurai T, Graham C, Vidler J, Kulasekararaj A, Patten PEM, Doores KJ, Irshad S. Abdul-Jawad S, et al. Among authors: alaguthurai t. Haematologica. 2022 May 1;107(5):1181-1184. doi: 10.3324/haematol.2021.280337. Haematologica. 2022. PMID: 35045695 Free PMC article. No abstract available.
Boosting of Waned Humoral and Cellular Responses to SARS-CoV-2 Variants of Concern Among Patients with Cancer.
McKenzie DR, Graham R, Lechmere T, Domingo-Vila C, Alaguthurai T, Arman C, Pollock E, Gousis C, Kakkassery H, Carpenter E, Kurshan A, Vidler J, Kulasekararaj A, Patten P, North BV, Tree T, Doores KJ, Hayday AC, Irshad S. McKenzie DR, et al. Among authors: alaguthurai t. Cancer Res Commun. 2022 Nov 17;2(11):1449-1461. doi: 10.1158/2767-9764.CRC-22-0298. Cancer Res Commun. 2022. PMID: 36824220 Free PMC article.
For all cohorts, virus-neutralizing immunity was significantly depleted over a period of up to 9 months following the second vaccine dose, the one striking exception being IL2 production by SARS-CoV-2 antigen-specific T cells. Immunity was restored by the third vaccine dos …
For all cohorts, virus-neutralizing immunity was significantly depleted over a period of up to 9 months following the second vaccine dose, t …
Assessing CSF ctDNA to Improve Diagnostic Accuracy and Therapeutic Monitoring in Breast Cancer Leptomeningeal Metastasis.
Fitzpatrick A, Iravani M, Mills A, Childs L, Alaguthurai T, Clifford A, Garcia-Murillas I, Van Laere S, Dirix L, Harries M, Okines A, Turner NC, Haider S, Tutt ANJ, Isacke CM. Fitzpatrick A, et al. Among authors: alaguthurai t. Clin Cancer Res. 2022 Mar 15;28(6):1180-1191. doi: 10.1158/1078-0432.CCR-21-3017. Clin Cancer Res. 2022. PMID: 34921020 Free PMC article.
Acute Immune Signatures and Their Legacies in Severe Acute Respiratory Syndrome Coronavirus-2 Infected Cancer Patients.
Abdul-Jawad S, Baù L, Alaguthurai T, Del Molino Del Barrio I, Laing AG, Hayday TS, Monin L, Muñoz-Ruiz M, McDonald L, Francos Quijorna I, McKenzie D, Davis R, Lorenc A, Chan JNE, Ryan S, Bugallo-Blanco E, Yorke R, Kamdar S, Fish M, Zlatareva I, Vantourout P, Jennings A, Gee S, Doores K, Bailey K, Hazell S, De Naurois J, Moss C, Russell B, Khan AA, Rowley M, Benjamin R, Enting D, Alrifai D, Wu Y, Zhou Y, Barber P, Ng T, Spicer J, Van Hemelrijck M, Kumar M, Vidler J, Lwin Y, Fields P, Karagiannis SN, Coolen ACC, Rigg A, Papa S, Hayday AC, Patten PEM, Irshad S. Abdul-Jawad S, et al. Among authors: alaguthurai t. Cancer Cell. 2021 Feb 8;39(2):257-275.e6. doi: 10.1016/j.ccell.2021.01.001. Epub 2021 Jan 5. Cancer Cell. 2021. PMID: 33476581 Free PMC article.
This is not the case for hematological malignancies, with virus-exposed patients collectively displaying heterogeneous humoral responses, an exhausted T cell phenotype and a high prevalence of prolonged virus shedding. ...
This is not the case for hematological malignancies, with virus-exposed patients collectively displaying heterogeneous humoral responses, an …
Humoral and cellular immunity to delayed second dose of SARS-CoV-2 BNT162b2 mRNA vaccination in patients with cancer.
McKenzie DR, Muñoz-Ruiz M, Monin L, Alaguthurai T, Lechmere T, Abdul-Jawad S, Graham C, Pollock E, Graham R, Sychowska K, Seow J, Tremain C, Gousis C, Domingo-Vila C, Cooper J, Vidler J, Owczarczyk K, Swampillai A, Kristeleit H, Malim MH, Fields P, Patten PEM, Papa S, North BV, Tree T, Doores KJ, Hayday AC, Irshad S. McKenzie DR, et al. Among authors: alaguthurai t. Cancer Cell. 2021 Nov 8;39(11):1445-1447. doi: 10.1016/j.ccell.2021.10.003. Epub 2021 Oct 12. Cancer Cell. 2021. PMID: 34678151 Free PMC article. No abstract available.
Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study.
Monin L, Laing AG, Muñoz-Ruiz M, McKenzie DR, Del Molino Del Barrio I, Alaguthurai T, Domingo-Vila C, Hayday TS, Graham C, Seow J, Abdul-Jawad S, Kamdar S, Harvey-Jones E, Graham R, Cooper J, Khan M, Vidler J, Kakkassery H, Sinha S, Davis R, Dupont L, Francos Quijorna I, O'Brien-Gore C, Lee PL, Eum J, Conde Poole M, Joseph M, Davies D, Wu Y, Swampillai A, North BV, Montes A, Harries M, Rigg A, Spicer J, Malim MH, Fields P, Patten P, Di Rosa F, Papa S, Tree T, Doores KJ, Hayday AC, Irshad S. Monin L, et al. Among authors: alaguthurai t. Lancet Oncol. 2021 Jun;22(6):765-778. doi: 10.1016/S1470-2045(21)00213-8. Epub 2021 Apr 27. Lancet Oncol. 2021. PMID: 33930323 Free PMC article.